Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
August 15, Wednesday 2018 2:14 PM       

       HEADLINES: Chemmanam Chacko passes away                                              Let contentious issues, extraneous debates not distract us: Prez's I-Day message to the nation                                              Erdogan says Turkey to 'boycott' US electronic goods                                              Kohli's plea to fans: Never give up on us                                              David Silva bids adieu to International football                                              13 players including Sanju Samsom served show-cause notice                                              Kaumudi Facebook
       SCI&TECH Next Article: Here is how you can travel smart using these apps!  
       A new ray of hope for breast cancer patients!
 
         Posted on :23:35:15 Mar 22, 2018
   
A A
       Last edited on:23:35:15 Mar 22, 2018
         Tags: Three-part molecule, Breast cancer patients
 

WASHINGTON DC: A new ray of hope has been found for breast cancer patients.

A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, according to a study conducted by the Medical College of Georgia at Augusta University.

This chimera, created by a team at the Georgia Cancer Center, has the ability to simultaneously decrease the expression of three growth factors that are over-expressed in some cancers.

The growth factors are human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and epidermal growth factor receptor (EGFR).

The new chimera interferes with HER2 and HER3 signaling and ultimately leads to cancer cell death.

"When HER2 is expressed in a cell, you'll usually find high expression of HER3, too," said researcher Hongyan Liu.

Extensive studies have found that 20-30 percent of breast cancers are characterized by over-expression of HER2, which makes the cancer cells grow and divide faster, leading to a cancer that's more aggressive and more likely to be resistant to the standard of care.

Patients with this type of breast cancer tend to have a poorer prognosis. "As a bioengineer, I am developing the materials for cancer-targeted treatment," Liu said.

"I have experience building multifunctional chimeras to target different types of genes associated with cancer cells."

Liu and her team created their molecule to target HER family receptors EGFR, HER2, and HER3 all at once, since it is well-known that another HER family member can compensate for one that is blocked by a drug having a single target.

Each component of this tripartite molecule has potent anti-tumor activity. The molecule was designed such that the EGFR-targeting component is sandwiched between the HER2- and HER3-targeting components in what is known as a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera.

This construction enables the EGFR component to reach its target within HER2- and HER3-expressing cells. Compared to individual components, the chimera is large enough to avoid renal depletion, resulting in a prolonged circulation time and increased efficiency.

The newly crafted molecule is non-toxic, simple to produce, and cost-effective compared to the production of alternate treatment strategies, such as antibodies and small molecule inhibitors.

Liu's ongoing studies are testing the ability of the three-in-one chimera to treat breast cancers that are resistant to Herceptin, a drug that targets HER2.

This work is being done in collaboration with Dr. Hasan Korkaya who has developed drug-resistant cell lines, and with breast cancer clinicians.

"We need to prove that this molecule will work on Herceptin-resistant breast cancer patients," Liu said.

Since other cancers, such as lung and head and neck, proliferate due to HER family over-expression, Liu anticipates that the chimera's utility will not be limited to breast cancers alone.

The findings from this study are published in the publication Molecular Therapy: Nucleic Acids.

A A
       SCI&TECH
Next Article: Here is how you can travel smart using these apps!
 
 
SCI&TECH HEADLINES
Here's what you may not know about H2O  
Alexa will tell you when it has done its homework  
Students recreate horrific atomic bombings of Hiroshima using VR technology  
Study discovers compounds that can reverse cell ageing  
Online interactive courses on AI in trading, first time on internet  
Apple to fix devices damaged by Japan's floods for free  
IT industry should focus on developing new technologies  
Skype adds read receipts to chats  
Mobile app for replacement of transformers in Raj  
Kashmiri students make solar boat for Dal Lake  
NASA prepares to fly probe into Sun's scorching atmosphere  
Yoga helps against non-communicable diseases: WHO  
Spironolactone can help prevent acne: Study  
Older Amazonian forests help regulate global climate  
Goal conflict linked to depressive symptoms  
A new world: Top 10 new species for 2018  
Beat the risk of frailty with healthy heart  
Twitter to hide trolls that hurl abuse: Twitter CEO  
Fortnite is finally coming to Android  
This test could detect signs of pancreatic cancer  
Aliens exist but may be in parallel Universe: Study  
This is your heart on nitric oxide  
Is your kid's heart clock ticking right?  
Do at-risk adolescents show depressive symptoms on social media?  
NASA launches Insight spacecraft to Mars for deepest dig yet  
 
Do you think there is pressure on police not to arrest Jalandhar bishop Fr Franco?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy